Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CMS121 in Healthy Volunteers
NCT05318040Phase 1Completed
- Sponsor
- Virogenics, Inc.
- Start
- May 2022
- Primary completion
- Dec 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CMS121 in Alzheimer's disease (AD) (7 arms), sponsored by Virogenics, Inc. Primary endpoint: Treatment-emergent adverse events. Started May 2022; status: completed.
02
Drugs
CMS121
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05318040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05318040.